Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma

机译：氟替卡松糠酸酯/维兰特罗92/22 µg每天一次：一项为期12个月的研究研究了轻度至中度哮喘的预后

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Fluticasone furoate/vilanterol (FF/V) is an effective long-acting β2 agonist/inhaled corticosteroid combination for managing persistent bronchial asthma. The aim of the study was to assess the outcomes achievable in patients with mild to moderate asthma receiving FF/V 92/22 µg once daily for 12 months.

机译：背景：糠酸氟替卡松/维兰特罗（FF / V）是一种有效的长效β2激动剂/吸入皮质类固醇激素组合，可用于治疗持续性支气管哮喘。该研究的目的是评估每天一次接受FF / V 92 /22μg的轻度至中度哮喘患者可达到的结果，持续12个月。

著录项

期刊名称 Therapeutic Advances in Respiratory Disease
作者
Roberto W. Dal Negro; Luca Bonadiman; Paola Turco;
展开▼
作者单位

展开▼
年(卷),期 2018(12),-1
年度 2018
页码 1753466618789894
总页数 8
原文格式 PDF
正文语种
中图分类呼吸生理学;
关键词
adherence to treatment clinical outcomes fluticasone furoate/vilanterol mild to moderate asthma time dependency;

机译：坚持治疗;临床结果;氟替卡松糠酸酯/维兰特罗;轻度至中度哮喘;时间依赖性;

相似文献

外文文献
中文文献
专利

1. Fluticasone furoate/vilanterol 92/22 μg once a day: a 12-month study on outcomes in mild to moderate asthma [J] . Roberto W. Dal Negro, Luca Bonadiman, Paola Turco Therapeutic advances in respiratory disease. . 2018,第2期

机译：氟替卡松糠酸酯/维兰特罗92/22μg，每天一次：一项12个月的轻度至中度哮喘预后研究
2. Fluticasone furoate/vilanterol 92/22 mu g once a day: a 12-month study on outcomes in mild to moderate asthma [J] . Dal Negro Roberto W., Bonadiman Luca, Turco Paola Therapeutic advances in respiratory disease. . 2018,第1期

机译：每天一次氟哌啶酮呋喃/ vilanterol 92/22 mu g：对轻度至中度哮喘的结果进行12个月的研究
3. Fluticasone furoate/Vilanterol 92/22?μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6?μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma [J] . Roberto W. Dal Negro, Chiara Distante, Luca Bonadiman, Multidisciplinary Respiratory Medicine . 2016,第1期

机译：氟替辛呋喃/ vilanterol 92/22？μg一次性对伯塞塞酮二丙酸酯/福莫特尔100/6？μgb.i.d .: 6周内分析温和至中等哮喘
4. Effectiveness of various regimens of maintaining anti-inflammatory therapy in mild to moderate asthmatic children: results of the prospective multicenter randomized trial [C] . Tereshchenko S., Smirnova S., Novitckii I., World Asthma, Allergy COPD Forum . 2014

机译：各种方案在轻度至中度哮喘儿童中维持抗炎治疗方案的有效性：前瞻性多中心随机试验的结果
5. Acupuncture therapy as adjunctive treatment in adult patients with mild to moderate persistent asthma [D] . Ansari, Zenas 2016

机译：针灸疗法作为成人轻度至中度持续性哮喘的辅助治疗
6. Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma [O] . Roberto W. Dal Negro, Luca Bonadiman, Paola Turco 2018

机译：每天一次糠酸氟替卡松/ Vilanterol 92/22μgvs丙酸倍氯米松/福莫特罗100/6μgb.I.D .: 12个月比较轻度至中度哮喘
7. Correction to: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma [O] . Roberto W. Dal Negro, Luca Bonadiman, Paola Turco 2018

机译：校正至：氟替塞呋喃/ vilanterol92/22μg一次性对弗洛米替纳酮二维替换/福莫特罗100/6μgb.i.d.:3月：在温和至中等哮喘中的结果的12个月比较

Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma

摘要

著录项

相似文献

相关主题

期刊订阅